Research programme: microRNA based diagnostics and therapeutics - Marina Biotech/Rosetta GenomicsAlternative Names: Rare disease diagnostics and therapeutics - Marina Biotech/Rosetta Genomics
Latest Information Update: 06 Nov 2015
At a glance
- Originator Rosetta Genomics
- Developer Marina Biotech; Rosetta Genomics
- Class Diagnostic agents; MicroRNAs
- Mechanism of Action MicroRNA modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Duchenne muscular dystrophy; Myotonic dystrophy; Neuromuscular disorders